VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research report sent to investors on Thursday. The firm issued a sell rating on the stock.

Several other brokerages have also recently issued reports on VNRX. HC Wainwright began coverage on shares of VolitionRx in a report on Tuesday, April 8th. They issued a “buy” rating and a $2.50 target price on the stock. D. Boral Capital reiterated a “buy” rating and set a $5.00 price target on shares of VolitionRx in a research note on Wednesday, April 30th.

VolitionRx Trading Down 5.2%

Shares of VNRX stock opened at $0.43 on Thursday. VolitionRx has a 12-month low of $0.42 and a 12-month high of $0.90. The firm’s 50 day moving average is $0.51 and its 200 day moving average is $0.59. The stock has a market capitalization of $43.32 million, a P/E ratio of -1.19 and a beta of 1.00.

Insider Activity

In related news, CEO Cameron John Reynolds purchased 181,818 shares of VolitionRx stock in a transaction on Wednesday, March 26th. The shares were bought at an average cost of $0.55 per share, for a total transaction of $99,999.90. Following the acquisition, the chief executive officer now owns 2,299,222 shares in the company, valued at approximately $1,264,572.10. The trade was a 8.59% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.40% of the company’s stock.

Institutional Trading of VolitionRx

Institutional investors and hedge funds have recently bought and sold shares of the stock. Northern Trust Corp increased its stake in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after acquiring an additional 28,579 shares during the last quarter. Two Sigma Securities LLC bought a new stake in VolitionRx during the fourth quarter worth approximately $29,000. Millennium Management LLC bought a new stake in VolitionRx during the fourth quarter worth approximately $36,000. Finally, Lagoda Investment Management L.P. increased its stake in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after acquiring an additional 1,481,000 shares during the last quarter. 8.09% of the stock is currently owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.